What are the best estimates of pediatric asthma control?

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 2, 2006, Pages 106-112

  Gandhi, Radha K ^a   Blaiss, Michael S ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE   (United States)

Author keywords

Asthma control; Asthma outcomes

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; NITRIC OXIDE; SHORT ACTING DRUG;

ABSENTEEISM; AIRWAY; ASTHMA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE MARKER; EMERGENCY WARD; EOSINOPHIL; EVALUATION; EXERCISE INDUCED ASTHMA; EXHALATION; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MEDICAL PARAMETERS; MORBIDITY; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCHOOL; SPIROMETRY; SPUTUM ANALYSIS; SYMPTOM; WHEEZING; FEMALE; INFANT; MALE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ASTHMA; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NITRIC OXIDE; OUTCOME ASSESSMENT (HEALTH CARE); PEAK EXPIRATORY FLOW RATE; SPIROMETRY;

EID: 33746803329     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000216853.18194.46     Document Type: Review

References (52)

1. Dey AN, Schiller JS, Tai DA. Summary Health Statistics for U.S. Children, National Health Interview Survey, 2002. Vital Health Stat 2004; 10 (221):1-78.
2. Jang AS, Lee JH, Park SW, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest 2005; 128:1140-1145. This article demonstrates the variable response to asthma treatment and identifies factors that may be used to guide treatment selection.
3. National Asthma Educational and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health: Bethesda; 2002.
4. Vollmer WM. Assessment of asthma control and severity. Ann Allergy Asthma Immunol 2004; 93:409-416, 492. This article reviews the differences between asthma severity and asthma control, and it also identifies instruments used to measure asthma control.
5. Hyland ME, Stahl E. Asthma treatment needs: a comparison of patients' and health care professionals' perceptions. Clin Ther 2004; 26:2141-2152. This retrospective observational study demonstrated that almost 75% of asthmatic patients experience an uncontrolled asthma episode one or more times over a 3-year period.
6. Stempel DA, McLaughin TP, Stanford RH, Fuhlbrigge AL. Patterns of asthma control: a 3-year analysis of patient claims. J Allergy Clin Immunol 2005; 115:935-939.
7. Covar RA, Cool C, Szefler SJ. Progression of asthma in childhood. J Allergy Clin Immunol 2005; 115:700-707. This article consists of a case presentation of childhood asthma exemplifying the variable nature of asthma and the markers useful in mentoring disease progression.
8. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61-67.
9. 1 measurement could predict the risk of an asthma exacerbation in the subsequent 3 years.
10. Brand PL, Roorda RJ. Usefulness of monitoring lung function in asthma. Arch Dis Child 2003; 88:1021-1025.
11. Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. Ann Allergy Asthma Immunol 2003; 91:398-404.
12. Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patientreported endpoints in clinical studies. Eur Respir J 2001; 17:220-224.
13. Yoos HL, Kitzman H, McMullen A, et al. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Ann Allergy Asthma Immunol 2002; 88:283-291.
14. Liu AH. Biomarkers and childhood asthma: improving control today and tomorrow. Allergy Asthma Proc 2005; 26:249-254. This article examines the role of biomarkers and lung function in assessing asthma management and makes recommendations on which markers should be implemented routinely.
15. McMullen AH, Yoos HL, Kitzman H. Peak flow meters in childhood asthma: parent report of use and perceived usefulness. J Pediatr Health Care 2002; 16:67-72.
16. Reddel HK, Vincent SD, Civitico J. The need for standardisation of peak flow charts. Thorax 2005; 60:164-167. This article examines the drawbacks of PEFR measurement related to variation in charts and provides alternative options to further standardize PEFR measurement.
17. Kamps AW, Roorda RJ, Brand PL. Peak flow diaries in childhood asthma are unreliable. Thorax 2001; 56:180-182.
18. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159 (Pt 1):1043-1051.
19. Strunk RC, Szefler SJ, Phillips BR, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003; 112:883-892.
20. Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35:1175-1179. This article evaluated eNO as a marker of eosinophilic airway inflammation and found a significant positive relationship between eNO and sputum eosinophil count.
21. Battaglia S, den Hertog H, Timmers MC, et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60:639-644. This article evaluated the small airways as a source of inflammation in asthma. It found that FeNO and 8-isoprostane in exhaled air correlated with small-airway function in mild asthma.
22. 1.
23. Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004; 169:473-478. This is a prospective study in unselected patients with undiagnosed respiratory symptoms confirming the diagnostic ability of eNO.
24. Harkins MS, Fiato KL, Iwamoto GK. Exhaled nitric oxide predicts asthma exacerbation. J Asthma 2004; 41:471-476. eNO was found to be unique among other parameters in predicting asthma exacerbations in 12 out of 22 patients with unstable asthma.
25. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:418-424.
26. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173. This is a randomized controlled trial of the use of eNO in adjusting doses of ICS. The use of eNO measurements allowed a lower dose of ICS to be used by up to 40% when other markers of inflammation and lung function were unchanged.
27. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60:215-218. This prospective study examined 40 children with asthma on controllers with ICS and followed eNO levels after discontinuation of ICS. Exhaled nitric oxide was found to be an early marker predicting relapse of asthma after cessation of ICS.
28. Berkman N, Avital A, Breuer R, et al. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005; 60:383-388. In this study the ability of eNO to diagnose asthma was compared to bronchial provocation studies. eNO was found to be as efficient as methacholine in diagnosing asthma.
29. Gabriele C, Pijnenburg MW, Monti F, et al. The effect of spirometry and exercise on exhaled nitric oxide in asthmatic children. Pediatr Allergy Immunol 2005; 16:243-247. This article examines the effects of prior spirometry and exercise on eNO values in 24 children with asthma. Both spirometry and exercise were shown to affect eNO levels: children should not exercise 30 min prior to eNO measurement.
30. Marteus H, Tornberg DC, Weitzberg E, et al. Origin of nitrite and nitrate in nasal and exhaled breath condensate and relation to nitric oxide formation. Thorax 2005; 60:219-225. This article examines the sources of eNO and found that eNO is influenced by dietary intake due to bacterial activity in the oropharyngeal tract.
31. Buchvald F, Baraldi E, Carraro S, et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol 2005; 115:1130-1136. This article establishes that eNO levels are low in normal children aged 4-17 years and that children at 4 years of age had difficulty in performing eNO but by 10 years 100% of children could complete eNO measurements.
32. Covar RA, Spahn JD, Martin RJ, et al. Safety and application of Induced sputum analysis in childhood asthma. J Allergy Clin Immunol 2004; 114:575-582. This article outlines the analysis of induced sputum in children as a marker of eosinophilic inflammation and loss of asthma control and found it correlated with peripheral eosinophilia and AHR.
33. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721.
34. Naureckas ET, Dukic V, Bao X, Rathouz P. Short-acting beta-agonist prescription fills as a marker for asthma morbidity. Chest 2005; 128:602-608. This article evaluates the relationship between short-acting β-agonist refills and impending emergency-department visits and hospitalizations. It found that a strong association between the two exists, suggesting that short-acting β-agonist refills may serve as a marker for asthma morbidity.
35. Wensley D, Silverman M. Peak flow monitoring for guided self-management in childhood asthma: a randomized controlled trial. Am J Respir Crit Care Med 2004; 170:606-612.
36. Yoos HL, Kitzman H, McMullen A, Sidora K. Symptom perception in childhood asthma: how accurate are children and their parents? J Asthma 2003; 40:27-39.
37. Bentur L, Beck R, Shinawi M, et al. Wheeze monitoring in children for assessment of nocturnal asthma and response to therapy. Eur Respir J 2003; 21:621-626.
38. Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J 2005; 12:265-270.
39. Luskin AT. What the asthma end points we know and love do and do not tell us. J Allergy Clin Immunol 2005; 115 (Suppl):S539-S545. This article evaluates outcome measures of asthma and the variable nature of asthma phenotypes based on genetics, environment and the variation in response to treatment.
40. Ford ES, Mannino DM, Redd SC, et al. Determinants of quality of life among people with asthma: findings from the Behavioral Risk Factor Surveillance System. J Asthma 2004; 41:327-336.
41. Schatz M, Mosen D, Apter AJ, et al. Relationships among quality of life, severity, and control measures in asthma: an evaluation using factor analysis. J Allergy Clin Immunol 2005; 115:1049-1055. This article evaluates validated psychometric tools in measuring asthma-related quality of life, asthma control, and asthma severity. It found that asthma severity or control could not be distinguished from symptom frequency based on these tools alone.
42. Eisner MD, Ackerson LM, Chi F, et al. Health-related quality of Life and future health care utilization for asthma. Ann Allergy Asthma Immunol 2002; 89:46-55.
43. Okelo SO, Wu AW, Krishnan JA, et al. Emotional quality-of-life and outcomes in adolescents with asthma. J Pediatr 2004; 145:523-529. This article examines emotional quality of life and asthma morbidity in adolescents with asthma and found that emotional symptoms related to asthma are common in adolescents. These emotional symptoms are also related to increased morbidity, healthcare use, and school absenteeism.
44. Strine TW, Ford ES, Balluz L, et al. Risk behaviors and health-related quality of life among adults with asthma: the role of mental health status. Chest 2004; 126:1849-1854. This study, via the Behavioral Risk Factor Surveillance System, reveals that frequent mental distress is highly prevalent among persons with asthma, suggesting a synergistic effect of these two conditions.
45. Ford ES, Mannino DM, Redd SC, et al. Determinants of quality of life among people with asthma: findings from the Behavioral Risk Factor Surveillance System. J Asthma 2004; 41:327-336.
46. Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001; 163:924-929.
47. Gendo K, Lodewick MJ. Asthma economics: focusing on therapies that improve costly outcomes. Curr Opin Pulmon Med 2005; 11:43-50. This is a very thorough review of available studies evaluating asthma costs and therapies which are cost-effective. It found that most asthma-related hospitalizations and emergency-room visits are preventable and that combination therapies in asthma improve asthma compliance and decrease costs.
48. Flores G, Abreu M, Tomany-Korman S, Meurer J. Keeping children with asthma out of hospitals: parents' and physicians' perspectives on how pediatric asthma hospitalizations can be prevented. Pediatrics 2005; 116:957-965.
49. Lucas LR. Optimizing treatment outcomes for asthma. Allergy Immunol Rep 2005; 2:9-14. This article reviews varying phenotypes of asthma and defines asthma control. It also outlines new outcome measures and their role in optimizing asthma treatment.
50. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
51. Nathan RA. Measuring asthma control in clinical practice. Respiratory Dig 2005. http://www.aaaai.org/aadmc/resdigest/nathan.pdf [Accessed 9 January 2006].
52. Liu AH, Zeiger RS, Welch M, et al. Development and validation of a patientbased measure of asthma control in children (Childhood ACT). Presented at the Annual Meeting of the American College of Allergy, Asthma, & Immunology (ACAAI), Anaheim, California, 4-9 November 2005. Abstract no. 35.